

To: 5.1.2e [5.1.2e @rivm.nl]; 5.1.2e [5.1.2e @rivm.nl]; 5.1.2e
 5.1.2e 5.1.2e @rivm.nl]
From: 5.1.2e
Sent: Thur 2/22/2024 1:38:25 PM
Subject: RE: Draft proposal - post-COVID biomarkers
Received: Thur 2/22/2024 1:38:25 PM

Dat zijn grote namen, dus staat goed op het voorstel

From: 5.1.2e < 5.1.2e @rivm.nl>
Sent: Thursday, February 22, 2024 9:26 AM
To: 5.1.2e < 5.1.2e @rivm.nl>; 5.1.2e < 5.1.2e @rivm.nl>
Cc: 5.1.2e < 5.1.2e @rivm.nl>
Subject: FW: Draft proposal - post-COVID biomarkers

Hi 5.1.2e

Dat lijken me mooie namen om toe te voegen toch?

Reageren jullie naar 5.1.2e

Vriendelijke groeten,

5.1.2e

.....
Center for Infectious Disease Control | Epidemiology and surveillance unit | Department Enteric, Vectorborne and Zoonotic infections (EVZ)
Dutch National Institute for Public Health and the Environment
 PO Box 1 | 3720 BA Bilthoven
 Antonie van Leeuwenhoeklaan 9 | 3721 MA Bilthoven

T 5.1.2e
M 5.1.2e @rivm.nl
<http://www.rivm.nl>

Available at 5.1.2e

.....
RIVM Committed to health and sustainability

From: 5.1.2e < 5.1.2e @radboudumc.nl>
Sent: woensdag 21 februari 2024 14:24
To: 5.1.2e < 5.1.2e @rivm.nl>
Cc: 5.1.2e < 5.1.2e @rivm.nl>; 5.1.2e < 5.1.2e @rivm.nl>
Subject: Re: Draft proposal - post-COVID biomarkers

Dear 5.1.2e

Very nice proposal. No further comments.

5.1.2e ask me whether we can add more team members from Nijmegen to the proposal.

I discussed this within our team.

We can add:

5.1.2e

Maybe 5.1.2e I have to send her the proposal, thereafter she will decide).
 All from department of internal medicine, Radboudumc and infectious diseases specialists.

Al the best,

5.1.2e

Van: 5.1.2e <5.1.2e@rivm.nl>

Datum: dinsdag, 20 februari 2024 om 13:09

Aan: 5.1.2e <5.1.2e@radboudumc.nl>

CC: 5.1.2e <5.1.2e@rivm.nl>, 5.1.2e
<5.1.2e@rivm.nl>

Onderwerp: RE: Draft proposal - post-COVID biomarkers

U ontvangt niet vaak e-mail van 5.1.2e @rivm.nl. [Meer informatie over waarom dit belangrijk is](#)

Dear 5.1.2e

I hope you are well.

I have not heard from you regarding the pre-proposal about post-COVID-related biomarkers. I wondered whether you have received my email – hence my reminder.

In the meantime, I send you the updated version of the pre-proposal (based on the comments by the other members of our group). Of course in case you already started to write your comments onto the previous version that I've sent, please continue to do so. But if not, I would encourage you to use this new version of the preproposal.

The main request we have for you is to add any more people from your group at Radboud that you would like to involve in the grant proposal.

We plan to submit the preproposal this Friday, so we would be grateful if you can provide this information and your feedback, as soon as possible, preferably the end of today.

Thank you so much and please let me know in case you have any questions.

Best regards,

5.1.2e

From: 5.1.2e

Sent: donderdag 15 februari 2024 17:05

To: 5.1.2e @radboudumc.nl' <5.1.2e@radboudumc.nl>

Cc: 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e <5.1.2e@rivm.nl>

Subject: Draft proposal - post-COVID biomarkers

Dear 5.1.2e

I hope you are well.

The first draft of the post-COVID condition biomarker discovery grant proposal is ready. I added your email address to our Teams group – in the group in the General / Files section you can easily find the word document of the proposal pinned at the top.

Unfortunately sharing files with external emails via Teams does not always work, so just in case I also send you the draft in the attachment.

We will be grateful for your feedback! Would you be able to share your thoughts and feedback by the end of **Tuesday the 20th of February?** Please let us know in case you need more time.

Kind regards,

5.1.2e

.....
Immuunsurveillance (IMS) | Centrum immunologie van infectieziekten en vaccins (IIV)

Rijksinstituut voor Volksgezondheid en Milieu
Antonie van Leeuwenhoeklaan 9 | 3721 MA Bilthoven

.....
M 5.1.2e
5.1.2e @rivm.nl
<http://www.rivm.nl>
.....

RIVM De zorg voor morgen begint vandaag

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.
www.rivm.nl De zorg voor morgen begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.
www.rivm.nl/en Committed to health and sustainability

De informatie in dit bericht is uitsluitend bestemd voor de geadresseerde. Aan dit bericht en de bijlagen kunnen geen rechten worden ontleend. Heeft u deze e-mail onbedoeld ontvangen? Dan verzoeken wij u het te vernietigen en de afzender te informeren. Openbaar maken, kopiëren en verspreiden van deze e-mail of informatie uit deze e-mail is alleen toegestaan met voorafgaande schriftelijke toestemming van de afzender. Het Radboudumc staat geregistreerd bij de Kamer van Koophandel in het handelsregister onder nummer 80262783.

The content of this message is intended solely for the addressee. No rights can be derived from this message or its attachments. If you are not the intended recipient, we kindly request you to delete the message and inform the sender. It is strictly prohibited to disclose, copy or distribute this email or the information inside it, without a written consent from the sender. Radboud university medical center is registered with the Dutch Chamber of Commerce trade register with number 80262783.